INOVIQ and Promega sign a global joint marketing agreement for INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purificati...
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has been informed it will receive national reimbursement ...
Microba and Sonic Healthcare signed a commercial agreement to sell Microba's advanced infectious disease testing technology MetaPanel™ in Australia...
SciY is being launched by Bruker’s new Integrated Data Solutions division, in close collaboration with majority-owned software companies Mestrelab Re...
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has o...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that the U.S. Federal Bureau of Investigation (FBI) has approved its ForenSeq® Mains...
BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity 20,000-participant study reflects racial ...
Diatech Pharmacogenetics (“Diatech”) has established a collaboration agreement with Janssen Pharmaceutica NV with the aim of improving access t...
U.S. Food and Drug Administration announced a new voluntary pilot program for certain oncology drug products used with certain corresponding in vitro diagn...
· Bespoke lab and office space designed to foster innovation and collaboration with colleagues and customers H.E.L Group (H.E.L), a global ...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new systematic evaluation that underlines the unique benefits of the compa...
Genomill, a pioneering precision diagnostics company, brings its cutting-edge Geno1® platform to the collaboration. Genomill's proprietary and patented...
There are multiple drugs available to treat breast cancer. Most patients become drug resistant, meaning that the cancer cells aren't responding to the drug...
© 2025 Biopharma Boardroom. All Rights Reserved.
